Immunological changes and clinical effects of adoptive immunotherapy using lymphokine activated killer cells in patients with hepatocellular carcinoma.

概要

論文の詳細を見る
We investigated the immunolqgical characteristics in patients with hepatocellular carcinoma (HCC) and treated them with autologous lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rIL-2). We observed the following points:1) LAK activity was very low in all cases of HCC, 2) Impaired LAK activity was remarkably augmented by systemic administration of rIL-2, 3) LAK cells induced at high concentrations of rIL-2 (≥150 ng/ml) maintained high activity for 48 hours in the rIL-2 free medium.4) After LAK administration, mononuclear cells which were collected from surgical specimens of the HCC mass were found to be cytotoxic against autologous fresh HCC cells. On the basis of these findings, we transferred 1-10×10<SUP>9</SUP> LAK cells once or twice a week along with a daily administration of 15 μg rIL-2 to 11 patients with advanced HCC. In result, a more than 35 percent reduction of serum α-fetoprotein (AFP) was observed in 4 of 10 cases and a decrease in tumor size was observed in 2 of 11 cases without any serious side effects except for fever and eosinophilia.
社団法人日本肝臓学会の論文